Chelsie Derman

Check out the top 5 psychiatry headlines in August 2025, including the fast-track designation of NRX-100 for suicidal ideation.

Upstream Bio’s VIBRANT trial finds verekitug, a monoclonal antibody binding to the TSLP receptor, reduces nasal polyps in patients with CRSwNP.

This month in review features the top 5 allergy news in August 2025, including FDA approvals, updated guidelines, and emerging research.

FDA approval of weekly subcutaneous lecanemab-irmb offers at-home maintenance therapy for early Alzheimer’s after initial intravenous treatment.

The basophil activation test shows the greatest accuracy in predicting allergic reactions to baked and fresh cow’s milk, reducing the need for oral food challenges in children.

Combining salivary bacteria, serum markers, and past attack history improves risk prediction for severe asthma attacks in children.

Research links Treg activity, B-cell suppression, and gastrointestinal immune regulation to the success and failure of peanut oral immunotherapy.

Up to half of psoriasis patients report significant psychiatric symptoms, highlighting the importance of routine screening in practice.

WAO’s updated framework adds mixed N-ERD, mixed NECD, and extends the pediatric term NIUAA to adults.

Study highlights risk factors and diagnostic accuracy for immediate-type local anesthetic allergy in children.

Phase 2 data shows meaning-centered psychotherapy may strengthen psilocybin-assisted therapy for depression in patients with cancer and MDD.

Study reveals 7 communication strategies clinicians can use to convey allergy risk and guide adrenaline auto-injector decisions in pediatric consultations.

In a study, ADHD treatments were linked to reduced suicidal behavior, substance misuse, transport accidents, and criminality, but not accidental injuries.

MGH investigators confirmed the reliability of the Drug Allergy History Tool (DAHT), which outperformed EHR documentation in completeness.

In a new study, esketamine nasal spray improved anhedonia in treatment-resistant unipolar and bipolar depression, independent of general symptom changes.

Four allergens not on the FDA or EFSA food allergy list show high frequency in a recent study. Anaphylaxis induced by goat or sheep milk led to 2 deaths.

The FDA has approved Ionis Pharmaceuticals' donidalorsen to prevent HAE attacks in adults and children over 12 years.

A recent study shows combined treatment increases total and N3 sleep in just 3 days for patients with comorbid insomnia and depression.

A discrete choice experiment revealed food allergy treatment preferences among adolescents, with efficacy ranking as the most important attribute.

Single-dose psychedelic therapy (RE104 30 mg) shows rapid improvements in postpartum depression, offering a potential alternative to slow-acting therapies.

A review estimated that eliminating cerebrovascular disease could have prevented 1.5 to 1.8 million US dementia cases in 2020.

Survey reveals persistent misconceptions about blood pressure thresholds, symptoms, and management, with most patients willing to act on clinician advice.

Multicenter study finds most children with anaphylaxis can be safely discharged within 2 hours, with 4 hours for those with cardiovascular involvement.

A new advisory highlights cephalexin’s efficacy and low cross-reactivity risk, supporting its safe use in patients with penicillin allergy.

New research confirms that adrenaline is safe and effective for anaphylaxis, debunking myths.

Phase 4 data reveal esketamine outperforms standard antidepressants in reducing insomnia and boosting next-day well-being in patients with TRD.

Meta-analysis finds omalizumab and remibrutinib most effective for chronic urticaria unresponsive to antihistamines; cyclosporine has greater risks.

Real-world review finds Black patients report fewer dupilumab-related adverse events than White patients.

In a Chinese cohort, baricitinib achieved high hair regrowth rates in alopecia areata, totalis, universalis, and eyebrow/eyelash loss, with no serious adverse events.

Survey and RESONATE trial data suggest a -0.22-point drop in the Combined Symptom and Medication Score signal meaningful benefit.